232271-19-1
中文名稱
(ALPHAS)-ALPHA-[(2,6-二氯苯甲酰)氨基]-2',6'-二甲氧基聯(lián)苯-4-丙酸
英文名稱
N-(2,6-Dichlorobenzoyl)-4-(2,6-diMethoxyphenyl)-L-phenylalanine
CAS
232271-19-1
分子式
C24H21Cl2NO5
分子量
474.33
MOL 文件
232271-19-1.mol
更新日期
2026/05/25 13:08:20
232271-19-1 結(jié)構(gòu)式
基本信息
中文別名
化合物TR14035(S)-2-(2,6-二氯苯酰胺)-3-(2,6-二甲氧基-[1,1-聯(lián)苯]-4-基)丙酸
(ALPHAS)-ALPHA-[(2,6-二氯苯甲酰)氨基]-2',6'-二甲氧基聯(lián)苯-4-丙酸
英文別名
MDK1191MDK-1191
TR 14035
TR-14035
TR 14035
TR14035
TR 14035
TR14035
MDK-1191
MDK1191
N-(2,6-Dichlorobenzoyl)-4-(2,6-diMethoxyphenyl)-L-phenylalanine
(S)-2-(2,6-DichlorobenzaMido)-3-(2',6'-diMethoxy-[1,1'-biphenyl]-4-yl)propanoic acid
[1,1'-Biphenyl]-4-propanoic acid, α-[(2,6-dichlorobenzoyl)amino]-2',6'-dimethoxy-, (αS)-
(alphaS)-alpha-[(2,6-Dichlorobenzoyl)amino]-2',6'-dimethoxy-[1,1'-biphenyl]-4-propanoic acid
所屬類別
生物化工：激動劑抑制劑物理化學(xué)性質(zhì)
沸點604.0±55.0 °C(Predicted)
密度1.333
儲存條件2-8°C
儲存條件Sealed in dry,2-8°C
溶解度DMSO: ≥ 41 mg/mL (86.44 mM)
酸度系數(shù)(pKa)3.53±0.10(Predicted)
形態(tài)粉末
顏色White to off-white
(ALPHAS)-ALPHA-[(2,6-二氯苯甲酰)氨基]-2',6'-二甲氧基聯(lián)苯-4-丙酸價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/03/03 | S0314 | (ALPHAS)-ALPHA-[(2,6-二氯苯甲酰)氨基]-2',6'-二甲氧基聯(lián)苯-4-丙酸 TR-14035 | 232271-19-1 | 5mg | 2376.42元 |
| 2026/03/03 | S0314 | (ALPHAS)-ALPHA-[(2,6-二氯苯甲酰)氨基]-2',6'-二甲氧基聯(lián)苯-4-丙酸 TR-14035 | 232271-19-1 | 25mg | 6576.49元 |
| 2025/12/22 | HY-15770 | (ALPHAS)-ALPHA-[(2,6-二氯苯甲酰)氨基]-2',6'-二甲氧基聯(lián)苯-4-丙酸 TR-14035 | 232271-19-1 | 1 mg | 509元 |
常見問題列表
生物活性
TR-14035 (SB 683698, MDK-1191) 是一種 alpha4beta (α4β) integrin 雙效拮抗劑，對 alpha4beta7 (α4β7) 和 alpha4beta1 (α4β1) 的IC50值分別為7 nM和87 nM。靶點
| Target | Value |
|
α4β7
(Cell-free assay) | 7 nM |
|
α4β1
(Cell-free assay) | 87 nM |
體外研究
TR14035 blocks adhesion of RPMI-8866 cells to MAdCAM-Ig by 100% at 1μM, with an approximate IC
50
of 0.01μM.
體內(nèi)研究
TR-14035 (3?mg/kg; i.g.) produces a significant decrease of the airways hyper-responsiveness to 5-hydroxytryptamine (5-HT) in an experimental model of allergic asthma in Brown Norway rats.
TR-14035 exhibits plasma decreased with half-lives of 0.28 h (3 mg/kg for i.v.) and 0.39 h (10 mg/kg for i.g.), and the oral bioavailability (F) is 17%.
| Animal Model: | Male Brown Norway rats (250-300?g) |
| Dosage: | 3?mg/kg |
| Administration: | Oral gavage, 1?h before and 3?h after antigen challenge |
| Result: | Suppressed antigen-induced airway hyper-responsiveness and inflammation. |
| Animal Model: | Male Sprague-Dawley rats (250-320 g) |
| Dosage: | 3 mg/ kg for i.v.; 10 mg/kg for i.g. |
| Administration: | Intravenous injection and oral gavage |
| Result: | T 1/2 (1.88 h for i.v.; 3.42 h for i.g.), F (17%). |